CN112279860A - 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 - Google Patents
一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 Download PDFInfo
- Publication number
- CN112279860A CN112279860A CN201910677212.6A CN201910677212A CN112279860A CN 112279860 A CN112279860 A CN 112279860A CN 201910677212 A CN201910677212 A CN 201910677212A CN 112279860 A CN112279860 A CN 112279860A
- Authority
- CN
- China
- Prior art keywords
- compound
- cantharidin
- preparation
- cantharidin derivative
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical class C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 150000004982 aromatic amines Chemical group 0.000 title claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 15
- 229960000583 acetic acid Drugs 0.000 claims description 14
- 229940095758 cantharidin Drugs 0.000 claims description 14
- 229930008397 cantharidin Natural products 0.000 claims description 14
- 239000012362 glacial acetic acid Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 8
- 229940125758 compound 15 Drugs 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 7
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 7
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 7
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims description 7
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 7
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 7
- 229940126657 Compound 17 Drugs 0.000 claims description 7
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims description 7
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 7
- 230000000840 anti-viral effect Effects 0.000 claims description 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 7
- 229940126543 compound 14 Drugs 0.000 claims description 7
- 229940126142 compound 16 Drugs 0.000 claims description 7
- 229940125810 compound 20 Drugs 0.000 claims description 7
- 229940127204 compound 29 Drugs 0.000 claims description 7
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- -1 oral preparations Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 6
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 6
- 231100000417 nephrotoxicity Toxicity 0.000 abstract description 6
- 206010029155 Nephropathy toxic Diseases 0.000 abstract description 5
- 230000007694 nephrotoxicity Effects 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 3
- 230000002155 anti-virotic effect Effects 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 239000000443 aerosol Substances 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- 150000008064 anhydrides Chemical class 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 10
- 239000004810 polytetrafluoroethylene Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- 210000005084 renal tissue Anatomy 0.000 description 9
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 241000272201 Columbiformes Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 241000131283 Cantharis Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000005918 in vitro anti-tumor Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000272205 Columba livia Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical group C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004796 pathophysiological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 1
- LEWZOBYWGWKNCK-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=C2CCCC2=C1 LEWZOBYWGWKNCK-UHFFFAOYSA-N 0.000 description 1
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- JXYITCJMBRETQX-UHFFFAOYSA-N 4-ethynylaniline Chemical compound NC1=CC=C(C#C)C=C1 JXYITCJMBRETQX-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- CBTLTHNUFAXDBE-UHFFFAOYSA-N C12=CC=3OCOC=3C=C2C23CCN(C)C3CCC3C2OC1O3 Chemical compound C12=CC=3OCOC=3C=C2C23CCN(C)C3CCC3C2OC1O3 CBTLTHNUFAXDBE-UHFFFAOYSA-N 0.000 description 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 101710189648 Serine/threonine-protein phosphatase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 125000004093 cyano group Chemical class *C#N 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- ABRWESLGGMHKEA-UHFFFAOYSA-N n-tert-butylaniline Chemical compound CC(C)(C)NC1=CC=CC=C1 ABRWESLGGMHKEA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- LRTFPLFDLJYEKT-UHFFFAOYSA-N para-isopropylaniline Chemical compound CC(C)C1=CC=C(N)C=C1 LRTFPLFDLJYEKT-UHFFFAOYSA-N 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
Abstract
本发明提供了一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其在制备抗肿瘤、抗病毒药物中的应用和在制备功能食品中的应用,涉及药物技术领域。本发明中的斑蝥素衍生物可制备成各种形式的药物制剂,包括口服、注射、肺吸入制剂、透皮制剂,具体包括注射剂、口服液、片剂、胶囊剂、颗粒剂、气雾剂、粉雾剂、喷雾剂、贴剂等。本发明的斑蝥素衍生物在应用中具有较低的肾毒性和胃肠道反应,且能抑制多种肿瘤细胞和病毒。
Description
技术领域
本发明属于药物技术领域,具体涉及一种芳香胺取代的斑蝥素衍生物及其制备方法,以其为活性成分的药物组合物,以及它们在制备防治抗肿瘤、抗病毒药物和功能食品中的应用。
背景技术
斑蝥素(1,2-二甲基-3,6-氧代环己烷-1,2-邻二甲酸酐, 1,2-Dimethyl-3,6-epoxycyclohexane-1,2-dicarboxylic anhydride)是从昆虫纲动物斑蝥体液中分离得到具有亲酯性的萜类化合物。在室温下斑蝥素是一种无色无味的晶状固体。医学上斑蝥素外用具有皮肤止痒、改善局部神经营养及刺激毛根,促进毛发生长的作用,已经被用于治疗各种皮肤病(痔疮、溃疡、寻常疣和软疣等)。同时临床研究显示斑蝥素是一种丝氨酸/苏氨酸蛋白磷酸酶PP1和PP2A的抑制剂,可导致多种细胞效应,如DNA损伤,细胞周期停滞和细胞凋亡等,因此能够显著的抑制肝癌,胰腺癌,结肠癌,肺癌,黑色素瘤和膀胱癌细胞的生长。然而斑蝥素严重的肾毒性限制了其作为小分子药物的应用。虽然在近几十年里人们进行了大量的生理和生化研究,希望找到由斑蝥素引起的生长抑制及细胞死亡的原因,但是其主要的作用和通路分子机制仍然还不清楚。
近年来,人们将斑蝥素的多种衍生物作为潜在的抗肿瘤剂进行了深入研究,如申请号为14/504,564的美国专利公开了斑蝥素及其衍生物在制备抗肿瘤药物中的应用;申请号为10/703,336的美国专利公开了改进的斑蝥酸酐衍生物在抗肿瘤中的应用;申请号为CN201610451738.9的中国专利公开了一种去甲斑蝥素单酸单酯衍生物及其抗肿瘤应用。 |
临床上,这些衍生物具有与斑蝥素一样可引起细胞生长抑制活性的能力,然而也具有强抑制的肾毒性和肠胃毒性。斑蝥酸代表了最早商业化的斑蝥素抗肿瘤剂。但是,这些化合物也受限于它们对正常细胞的毒性,阻止了其作为有效的抗癌药物或化学疗法用于癌症的治疗。
同时,在申请号为CN01140066.8的中国专利中,公开了斑蝥酸酐的药物组合物具有抗病毒的作用,在申请号为CN200710087156.8的中国专利中,公开了去甲斑蝥素及其衍生物在预防和治疗艾滋病中的新用途,然而,仍然由于这类化合物具有较强的肾毒性和肠胃毒性,而限制了其使用。
因此,迫切需要开发其他新的斑蝥素衍生物来解决这些问题。
发明内容
本发明的目的,在于提供化合物芳香胺取代的斑蝥素衍生物为有效成分的抗肿瘤、抗病毒药物及其制备方法,及其此活性成分在制备抗肿瘤、抗病毒药物和制备抗肿瘤功能食品中的应用。
本发明的目的,是通过以下技术方案实现的:
一种斑蝥素衍生物,具有以下式(I)所示的结构通式:
其中,X和Y分别选自:氮,氧,碳,羰基;
R1选自:芳基、芳香杂环基及生物活性分子。
优选的,式(I)中的斑蝥素衍生物,其中,X优选为氮;Y优选为羰基,R1优选为芳基、芳香杂环基。
更优选的方案中,上述斑蝥素衍生物为化合物8、化合物9、化合物13、化合物14、化合物15、化合物16、化合物17、化合物18、化合物19、化合物20、化合物29、化合物30,
本发明还提供了上述斑蝥素衍生物的制备方法,为通过在冰醋酸溶液中缩合芳香胺与斑蝥素。
优选地,芳香胺与斑蝥素的缩合反应温度为115-145°C,反应时间为12-36h,更优选的,反应温度为135°C,反应时间为12h。
本发明还提供了一种药物组合物,含有式(I)所示的斑蝥素衍生物、其药学上可接受的盐、溶剂合物及可药用载体或赋形剂中的一种或多种。
同时还提供了另一种药物组合物,含有化合物8、化合物9、化合物13、化合物14、化合物15、化合物16、化合物17、化合物18、化合物19、化合物20、化合物29、化合物30及其药学上可接受的盐、溶剂合物及可药用载体或赋形剂中的一种或多种。
本发明提供的式(I)斑蝥素衍生物、其药学上可接受的盐、溶剂合物在制备抗肿瘤、抗病毒药物中的应用。
本发明提供的式(I)斑蝥素衍生物、其药学上可接受的盐、溶剂合物在制备功能食品中的应用。
化合物8、化合物9、化合物13、化合物14、化合物15、化合物16、化合物17、化合物18、化合物19、化合物20、化合物29、化合物30及其药学上可接受的盐、溶剂合物在制备功能食品中的应用。
其中,本说明书所用的术语“芳基,芳香杂环基”指单环,稠环芳香烃基,芳香杂环烃基,优选碳原子数为3-14的芳香烃基,芳香杂环烃基,包括苯基,萘基, 蒽基,菲基,苊基,吡咯基,唑基,咪唑基,噻唑基,咔唑基、吡啶基,吗啉基,哌嗪基,吡嗪基,吡唑基,吲哚基,喹啉基等;芳香杂环烃基,包括苯基,吡咯基,吡啶基,吗啉基,哌嗪基,吲哚基等。芳香基,芳香杂环基的取代基团有;氢,烷基,烯基、炔基、卤素,卤素取代烷基,烷氧基,卤素取代烷氧基,烷氨基,卤素取代烷氨基,硝基,氰基,烷氧羰基,烷氧烷氧基,烷氧烷氧基。
术语“芳香胺”指氨基取代的芳香基或芳香杂环基。
术语“药物组合物”指包含指定量的各指定成分的产品,以及直接或间接从指定量的各指定成分的组合产生的任何产品。
术语“药学上可接受的盐”指衍生自无机或有机酸或碱的任何盐。
本发明的式(I)化合物用作药物时,可以直接使用,或者以药物组合物的形式使用。该药物组合物含有0.1-99%,优选为0.5-90%的本发明的式(I)化合物, 其余为药物上可接受的,对人体和动物无毒和惰性的可药用载体和/或赋形剂。
所述的药用载体或赋形剂是一种或多种选自固体、半固体和液体稀释剂、超填料以及药物制品辅剂。将本发明的药物组合物以单位体重服用量的形式使用。斑蝥素衍生物的组合物采用制药和食品领域公认的方法制备成各种剂型,如液体制剂(注射剂、混悬剂、乳剂、 溶液剂、糖浆剂等)、固体制剂(片剂、胶囊剂、颗粒剂、冲剂等) 、喷剂、气雾剂等。本发明的药物可经注射(静脉注射、静脉滴注、 肌肉注射、腹腔注射、皮下注射)和口服、舌下给药、粘膜透析等给药途径进行抗肿瘤、抗病毒的治疗。
附图说明
图1:实施组对小鼠血清中BUN水平的影响;
图2:光学显微镜下肾组织块的病理生理变化。
具体实施方式
下面结合本发明的实施例对本发明进行进一步的解释说明,但本发明的内容并不局限与此。
实施例1
化合物8的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (39.2 mg, 0.2 mmol)、2-氨基-3-甲基吡啶 (26.0 mg, 0.24mmol)和冰醋酸 (0.5 mL),用聚四氟乙烯胶塞密封,油浴加热至135°C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,得到白色固体8 (16.0-34 mg, 28-59% yield)。1H NMR (300 MHz, CDCl3) δ 8.46 (d, J = 3.8 Hz,1H), 7.68 (d, J = 8.3 Hz, 1H), 7.32 – 7.28 (m, 1H), 4.72 – 4.71 (m, 2H), 2.25(s, 3H), 1.90 – 1.82 (m, 2H), 1.77 – 1.74 (m, 2H), 1.28 (s, 6H) ppm;MS (ESI)m/z Calcd for [C16H18N2O3+Na]+ 309.3, found 309.1;MS (ESI)m/z Calcd for[C16H18N2O3+H]+ 287.1390, found 287.1386。
化合物9的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (39.2 mg, 0.2 mmol)、4-氨基二苯醚 (44.5 mg, 0.24 mmol) 和冰醋酸 (0.5 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,得到淡黄色固体9 (19.0-36.0 mg, 29-50% yield)。1H NMR (300 MHz, CDCl3) δ 7.37 – 7.33 (m, 2H),7.27 – 7.24 (m, 2H), 7.15 – 7.11 (m, 1H), 7.06 – 7.03 (m, 4H), 4.68 (s, 2H),1.87 – 1.84 (m, 2H), 1.75 – 1.73 (m, 2H), 1.24 (s, 6H) ppm;MS (ESI)m/z Calcdfor [C22H21NO4+Na]+ 386.4, found 386.2;MS (ESI)m/z Calcd for [C22H21NO4+H]+364.1543, found 364.1540。
化合物13的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、6-氨基苯并噻唑 (90.1 mg, 0.6 mmol) 和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体13 (13.5 -45.0mg)。1H NMR (300MHz, CDCl3) δ 9.05 (s, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.95 (s, 1H), 7.46 (d,J = 8.7 Hz, 1H), 4.72 (s, 2H), 1.89 – 1.75 (m, 4H), 1.28 (s, 6H) ppm;13C NMR(75 MHz, CDCl3) δ 180.6, 155.4, 152.9, 134.1, 129.5, 124.8, 123.9, 120.3,84.1, 54.1, 23.8, 12.9 ppm;HRMS (ESI)m/z Calcd for [C17H16N2O3S+H]+ 329.0954,found 329.0957。
化合物14的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、5-氨基茚旦 (79.14 mg, 0.6 mmol) 和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体14 (81.3-132 mg)。1H NMR (300 MHz,CDCl3) δ 7.28 (d, J = 7.3 Hz, 1H), 7.11 (s, 1H), 7.00 (d, J = 7.6 Hz, 1H),4.68 (m, J = 1.7 Hz, 2H), 2.91 (d, J = 5.9 Hz, 4H), 2.13 – 2.03 (m, 2H), 1.86– 2.03 (m, 4H), 1.23 (s, 6H) ppm;13C NMR (75 MHz, CDCl3) δ 180.8, 145.2,144.8, 129.9, 124.6, 124.3, 122.5, 83.9, 53.9, 32.7, 32.5, 25.4, 23.7, 12.7ppm;HRMS (ESI)m/z Calcd for [C19H21NO3+H]+ 312.1594, found 312.1593。
化合物15的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、对甲氧基苯胺 (74.0 mg, 0.6mmol)和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135°C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体15 (28.7 -79.0mg)。1H NMR (300MHz, CDCl3) δ 7.20 (d, J = 8.9 Hz, 2H), 6.96 (d, J = 8.9 Hz, 2H), 4.68 (s,2H), 3.81 (s, 3H), 1.89 – 1.71 (m, 4H), 1.24 (s, 6H) ppm;13C NMR (75 MHz,CDCl3) δ 180.8, 159.3, 127.6, 124.6, 114.2, 83.9, 55.4, 53.9, 23.7, 12.8 ppm;HRMS (ESI)m/z Calcd for [C17H19NO4+H]+ 302.1387, found 302.1385。
化合物16的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、4-乙炔基苯胺 (64.5 mg, 0.55 mmol) 和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体16 (10.0-35 mg)。1H NMR (300MHz, CDCl3) δ 8.05 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 8.3 Hz, 2H), 4.71 (s,2H), 2.62 (s, 3H), 1.89 – 1.75 (m, 4H), 1.27 (s, 6H) ppm;13C NMR (75 MHz,CDCl3) δ 197.0, 180.2, 136.6, 136.1, 129.0, 126.4, 84.1, 54.2, 26.7, 23.8,12.9 ppm;HRMS (ESI)m/z Calcd for [C18H19NO4+H]+ 314.1387, found 314.1385。
化合物17的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐(98.1 mg, 0.5 mmol)、3-氨基-9-乙基咔唑 (126.9 mg, 0.6 mmol) 和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体17 (28.1 -79mg)。1H NMR(300 MHz, CDCl3) δ 8.06 (d, J = 7.7 Hz, 1H), 7.99 (s, 1H), 7.50 – 7.38 (m,3H), 7.32 (dd, J = 8.6 Hz, 1H), 7.25 – 7.20 (m, 1H), 4.75 (s, 2H), 4.38 –4.31 (m, 2H), 1.88 – 1.74 (m, 4H), 1.40 (t, J = 7.1 Hz, 3H), 1.28 (s, 6H)ppm;13C NMR (75 MHz, CDCl3) δ 181.3, 140.3, 139.4, 126.0, 123.9, 123.1, 122.5,120.7, 119.0, 108.7, 108.6, 84.0, 53.9, 37.6, 23.8, 13.7, 12.9 ppm;HRMS (ESI)m/z Calcd for [C24H24N2O3+H]+ 389.1860, found 389.1856。
化合物18的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐(98.1 mg, 0.5 mmol)、4-(4-吗啉基)苯胺 (107.0 mg, 0.6 mmol) 和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体18 (28.0-78.0 mg)。1H NMR(300 MHz, CDCl3) δ 7.18 (m, J = 8.9 Hz, 2H), 6.94 (d, J = 9.0 Hz, 2H), 4.68(s, 2H), 3.84 (d, J = 4.6 Hz, 4H), 3.16 (d, J = 4.4 Hz, 4H), 1.86 – 1.71 (m,4H), 1.24 (s, 6H) ppm;13C NMR (75 MHz, CDCl3) δ 180.9, 151.1, 127.1, 123.7,115.6, 84.0, 66.7, 53.9, 48.9, 23.7, 12.8 ppm;HRMS (ESI)m/z Calcd for[C20H24N2O4+H]+ 357.1809, found 357.1807。
化合物19的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐(98.1 mg, 0.5 mmol)、4-氨基联苯 (101.5 mg, 0.6 mmol) 和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至115 °C,搅拌反应12-36小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯 = 3:1),得到白色固体19 (28.1-78 mg)。1H NMR (300MHz, CDCl3) δ 7.67 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 7.3 Hz, 2H), 7.47 – 7.37(m, 5H), 4.72 (s, 2H), 1.88 – 1.74 (m, 4H), 1.27 (s, 6H) ppm;13C NMR (75 MHz,CDCl3) δ 180.7, 141.5, 140.0, 131.1, 128.8, 127.8, 127.6, 127.2, 126.7, 84.1,54.1, 23.8, 12.9 ppm;HRMS (ESI)m/z Calcd for [C22H21NO3+H]+ 348.1594, found348.1591。
化合物20的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、2-萘胺 (86.0 mg, 0.6 mmol)和冰醋酸 (1.0 mL),用聚四氟乙烯胶塞密封,油浴加热至115-145 °C,搅拌反应12-36小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯 = 3:1),得到白色固体20 (19.7-68.0 mg)。1H NMR(300 MHz, CDCl3) δ 7.93 – 7.82 (m, 4H), 7.52 – 7.49 (m, 2H), 7.40 – 7.36 (m,1H), 4.74 (m, 2H), 1.89 – 1.75 (m, 4H), 1.28 (s, 6H) ppm;13C NMR (75 MHz,CDCl3) δ 180.8, 133.1, 132.8, 129.4, 128.9, 128.2, 127.7, 126.7, 126.5,125.6, 124.0, 84.1, 54.1, 23.8, 12.9 ppm;HRMS (ESI)m/z Calcd for [C20H19NO3+H]+322.1438, found 322.1436。
化合物29的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、4-异丙基苯胺 (75 μl, 0.6 mmol) 和冰醋酸 (2.0 mL),用聚四氟乙烯胶塞密封,油浴加热至135 °C,搅拌反应12小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯=3:1),得到白色固体29 (60.0-97.0 mg, 34-79% yield)。1H NMR (300 MHz, CDCl3) δ 7.32 – 7.19 (m, 4H), 4.69 (s, 2H), 2.95 – 2.91 (m,1H), 1.84 – 1.75 (m, 4H), 1.26 – 1.23 (m, 12H) ppm;13C NMR (75 MHz, CDCl3) δ180.8, 149.3, 129.6, 127.1, 126.3, 84.1, 54.0, 33.9, 23.9, 23.8, 12.9 ppm;MS(ESI)m/z Calcd for [C19H23NO3+H]+314.1751, found 314.1755。
化合物30的制备
在装有搅拌子的10毫升耐压反应管中依次加入斑蝥酸酐 (98.1 mg, 0.5 mmol)、叔丁基苯胺 (88 μl, 0.6 mmol) 和冰醋酸 (2.0 mL),用聚四氟乙烯胶塞密封,油浴加热至115-145 °C,搅拌反应12-36小时。反应结束后,将混合液冷却到室温,减压浓缩,粗品通过薄层层析硅胶板分离(石油醚:乙酸乙酯 = 3:1),得到白色固体30 (52.7-97 mg, 24-89%yield)。1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.2Hz, 2H), 4.69 (s, 2H), 1.87 – 1.67 (m, 4H), 1.32 – 1.25 (m, 15H) ppm;13C NMR(75 MHz, CDCl3) δ 180.8, 151.5, 129.3, 126.1, 125.9, 84.1, 54.0, 31.3, 23.8,23.4, 12.9 ppm;MS (ESI)m/z Calcd for [C20H25NO3+H]+328.1907, found 328.1904。
实施例2:
按实施例1的方法先制得斑蝥素衍生物,按常规加注射液用水,精滤,灌封灭菌制成注射液。
实施例3:
按实施例1的方法先制得斑蝥素衍生物,将其溶于无菌注射用水中,搅拌使溶,用无菌抽滤漏斗过滤,再无菌精滤,分装于安瓿中,低温冷冻干燥后灭菌熔封得粉针剂。
实施例4:
按实施例1的方法先制得斑蝥素衍生物,按其与赋形剂重量比为 9:1 的比例加入赋形剂,制成粉剂。
实施例5:
按实施例1的方法先制得斑蝥素衍生物,按其与赋形剂重量比为 1:5-1:10的比例加入赋形剂,制粒压片。
实施例6:
按实施例1的方法先制得斑蝥素衍生物,按常规口服液制法制成口服液。
实施例7:
按实施例1的方法先制得斑蝥素衍生物,按其与赋形剂重量比为5:1的比例加入赋形剂,制成胶囊或颗粒剂或冲剂。
实施例8:
按实施例1的方法先制得斑蝥素衍生物,按其与赋形剂重量比为3:1的比例加入赋形剂,制成胶囊或颗粒剂或冲剂。
实施例9:
取按实施例1的方法先制得斑蝥素衍生物43.6克,加入淀粉570 克,乳糖180克,薄荷醇3克,羧甲基淀粉钠152克,制成含片,作为功能食品。
为了更好的理解本发明的实质,下面以本发明的试验例即本发明的式 (I)化合物斑蝥素衍生物与药用载体或赋形剂组成的药物组合物的药理作用结果来说明本发明的优异性,但不以此来限制本发明。
试验例1:
1.1斑蝥素衍生物(由本发明的上述实施例1所制得)的肾毒性测试
动物(雄性ICR小鼠,体重20±2g,由南京医学院提供)到达实验室后,预饲养一周,给以标准食物,自由饮水。标准条件下适应性饲养后,均分为3组,一组作为空白对照组,腹腔注射给予0.9%生理盐水;一组作为实验组,腹腔注射给以等体积的药物(以本发明的上述实施例1所制得的化合物15为代表);另外一组作为阳性对照组,腹腔注射给以等体积的去甲斑蝥素。实验组和阳性对照组连续给药6天,空白对照组给以等体积的生理盐水。末次给药24小时后,通过摘眼球收集血液,测试肾功能指标,然后,将小鼠通过脱臼处死后,收取肾脏,对肾组织进行病理学分析。
1.2血清肾功能指标测试
将上述收集到的血液样品在室温下放置2小时后,以3500rpm离心10分钟,收集上层血清。根据试剂盒说明书,用比色测定试剂盒确定血尿素氮(BUN)的血清水平(BUN是肾细胞损伤的敏感标志物,其血清升高表示肾损伤的发生)。结果如图1所示。
由图1可以看出,与空白对照组相比,腹腔注射给予去甲斑蝥素的阳性对照组显著升高血清BUN水平,表示去甲斑蝥素能导致肾损伤;采用实验组对血清BUN水平稍微升高,表明式(I)所制得的斑蝥衍生物导致肾损伤程度较小。
1.3肾组织的病理学观察
将肾组织切成5μm的小块,在15%福尔马林中浸泡固定8~10小时,并依次用30%、70%、85%、95%、99.8%(即为无水乙醇)的酒精脱水,每次脱水1小时。在无水乙醇与二甲苯体积比为1:1混合溶液中透明2小时,再用纯二甲苯分别浸渍处理2小时。选取熔点在52~54℃的石蜡,将肾组织块放在熔化的石蜡和二甲苯的体积比为1:1混合溶液中浸泡1~2小时,再移入熔化的石蜡液中,于55~57℃左右的温箱中浸渍3小时两次,以便于石蜡浸入组织内。将浸蜡后的块状肾组织包埋在石蜡中,并切片处理。制好的切片在37℃恒温干燥箱中干燥,二甲苯脱蜡,逐级经分级浓度的乙醇直至30%酒精,用苏木精-伊红染色法(haematoxylin and eosin,H&E)染色。经苏木精-伊红染色后,苏木精将细胞核染成蓝紫色,其它成分则被伊红染成粉红色。染色后的切片经梯度酒精脱水以及二甲苯透明后,迅速擦去肾组织块周围多余液体,滴加1~2滴中性树胶,将洁净盖玻片倾斜放下(避免出现气泡),封片后就制成永久性的玻片标本,在光学显微镜下观察肾组织块的病理生理变化。结果见图2。
如图2所示,空白对照组肾脏结构正常,边界清晰(图2A);图2B为阳性对照组,肾小球肿胀,肾小管坏死,出现空泡,表明去甲斑蝥素会导致小鼠肾脏病理性损伤;而在实验组(图2C)中,肾脏结构趋于正常,表明式(I)所制得的斑蝥衍生物具有较小的肾毒性。
试验例2:
斑蝥酸衍生物致家鸽的呕吐试验:
试验方法:健康成年家鸽(雌雄兼用,450~500g,由南京市江宁区青龙山动物繁殖场提供)到达实验室后,预饲养一周,给以标准食物,自由饮水。标准条件下适应性饲养后,均分为2组,每组20只,其中一组作为实验组,另外一组作为对照组,两组之间无显著性差异,具有可比性,末次给药前禁食12h。所有家鸽接受一个周期(5天)的药物注射,记录家鸽每天出现第一次呕吐的时间(呕吐潜伏期)和每天的呕吐次数。
实验组:翼下静脉注射给以本发明药物(4mmol/kg,由本发明的上述实施例1所制得);
对照组:翼下静脉注射给以等摩尔的去甲斑蝥素。
结果:家鸽呕吐试验结果如下表1所示。
表1.本发明的斑蝥衍生物所致的家鸽呕吐试验结果
由表2可知,与对照组相比,本发明的斑蝥素衍生物与对照组相比能明显减少家鸽的呕吐次数,具有较小的胃肠道反应率。
试验例3:
斑蝥素衍生物(由本发明的上述实施例1所制得)的体外抗肿瘤试验:
肿瘤细胞株:肝癌、肺癌、胃癌、胰腺癌、淋巴癌、白血病细胞、宫颈癌瘤株,由中国药科大学药理实验室提供;
试验方法:噻唑蓝还原法(MTT)
对本发明制备得到的式(I)化合物即斑蝥素衍生物进行体外抗肿瘤试验,分别将肝癌、肺癌、胃癌、胰腺癌、淋巴癌、白血病细胞、宫颈癌瘤株接种到96孔板中,制成浓度为5×104个/mL的细胞悬液。向96孔板中,每孔加入100μL细胞悬液(每孔5×103个细胞),于37℃、5%CO2培养箱中培养24小时;然后,药物用含3%FBS的DMEM培养基进行倍比稀释至所需的浓度,给药容积为100μl/孔,同时设立生理盐水空白对照组和去甲斑蝥素、斑蝥酸钠阳性对照组,空白对照组和阳性对照组也分别采用含3%FBS的DMEM培养基进行倍比稀释,再将96孔板置于37℃、5%CO2培养箱中培养72小时,然后每孔加20μlMTT(5mg/ml,PBS配),继续培养4小时,吸弃上清,每孔加入150μLDMSO溶解,在酶标仪上,振动10-15分钟轻轻混匀。在λ=570nm的波长下,用酶标仪检测每孔的吸光度即OD值,独立实验重复三次以上,以各复孔的平均值作为该细胞的OD值,按照下列公式计算生长抑制率(Inhibitionratio,IR)。
具体试验结果如表2所示:
表2斑蝥素衍生物对肿瘤细胞的抑制作用(IC50为半数抑制率)
由表2体外抗肿瘤试验结果可知,本发明提供的式(I)化合物即斑蝥素衍生物对多种肿瘤细胞均有较强的抑制作用,可以用于恶性肿瘤疾病的治疗。
试验例4:
斑蝥素衍生物(由本发明的上述实施例1所制得)的抗病毒试验:
病毒细胞:HepG2.2.15细胞、HIV感染的MT4细胞,由中国药科大学药理实验室提供;
试验方法,基本同试验例3,不同之处在于采用显微镜观察CPE(病变),设细胞对照组,实验组,阳性对照组1(恩替卡韦),阳性对照组2(齐多夫定),同时观察CPE。实验结果如表3所示。
具体试验结果如表3所示:
表3斑蝥素衍生物体外对病毒细胞的抑制作用
由表3体外抗病毒试验结果可知,本发明提供的式(I)化合物即斑蝥素衍生物对多种病毒细胞均有抑制作用,可以用于抗病毒疾病的治疗。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,本领域普通技术人员对本发明的技术方案所做的其他修改或者等同替换,只要不脱离本发明技术方案的精神和范围,均应涵盖在本发明的权利要求范围当中。
Claims (10)
2.根据权利要求1式(I)所述的斑蝥素衍生物,其特征在于:X优选为氮;Y优选为羰基,R1优选为芳基、芳香杂环基。
4.根据权利要求3所示的斑蝥素衍生物,其制备方法为通过在冰醋酸溶液中缩合芳香胺与斑蝥素。
5.根据权利要求4所示的斑蝥素衍生物,其特征在于:芳香胺与斑蝥素的缩合反应温度为115-145°C,反应时间为12-36h;优选反应温度为135°C,反应时间为12h。
6.一种药物组合物,其特征在于:含有权利要求1或2式(I)所示的斑蝥素衍生物、其药学上可接受的盐、溶剂合物及可药用载体或赋形剂中的一种或多种。
7.一种药物组合物,其特征在于:含有权利要求3所述的化合物8、化合物9、化合物13、化合物14、化合物15、化合物16、化合物17、化合物18、化合物19、化合物20、化合物29、化合物30、其药学上可接受的盐、溶剂合物及可药用载体或赋形剂中的一种或多种。
8.一种如权利要求1或2或3中所述的式(I)斑蝥素衍生物、其药学上可接受的盐、溶剂合物及可药用载体或赋形剂在制备抗肿瘤、抗病毒药物中的应用。
9.一种如权利要求1或2中所述的式(I)斑蝥素衍生物在制备功能食品中的应用。
10.一种如权利要求3所述的化合物8、化合物9、化合物13、化合物14、化合物15、化合物16、化合物17、化合物18、化合物19、化合物20、化合物29、化合物30在制备功能食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910677212.6A CN112279860A (zh) | 2019-07-25 | 2019-07-25 | 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910677212.6A CN112279860A (zh) | 2019-07-25 | 2019-07-25 | 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112279860A true CN112279860A (zh) | 2021-01-29 |
Family
ID=74419434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910677212.6A Pending CN112279860A (zh) | 2019-07-25 | 2019-07-25 | 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112279860A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101011543A (zh) * | 2005-12-30 | 2007-08-08 | 黄振华 | 一种新的抗肿瘤药物组合物 |
CN103483346A (zh) * | 2013-09-04 | 2014-01-01 | 西北农林科技大学 | 一种去甲斑蝥酰亚胺类衍生物及其制备方法和应用 |
-
2019
- 2019-07-25 CN CN201910677212.6A patent/CN112279860A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101011543A (zh) * | 2005-12-30 | 2007-08-08 | 黄振华 | 一种新的抗肿瘤药物组合物 |
CN103483346A (zh) * | 2013-09-04 | 2014-01-01 | 西北农林科技大学 | 一种去甲斑蝥酰亚胺类衍生物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
ING-JY TSENG 等: "Synthesis and evaluation of cantharidinimides on human cancer cells", 《JOURNAL OF EXPERIMENTAL AND CLINICAL MEDICINE》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104797581A (zh) | 杂芳基炔烃化合物及其应用 | |
CN113072591B (zh) | 铱配合物及其合成方法和应用 | |
JP4500672B2 (ja) | 抗炎症、抗ウイルスおよび抗血栓症活性を有するベンゾイソセレンアゾール誘導体ならびにそれらの使用 | |
CN101735276A (zh) | 水溶性磷酸单酯衍生物及其应用 | |
CN110938032A (zh) | 有机硒化合物及其用途 | |
CN111116667B (zh) | 基于8-羟基喹啉衍生物和1-苯基吡唑铱二聚体构筑的铱配合物及其合成方法和应用 | |
CN106673988B (zh) | 苄亚基环己烯酮衍生物及其制备方法和医药用途 | |
JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
CN107141284B (zh) | 黄连碱类衍生物、其制备方法、药物组合物及抗肿瘤用途 | |
KR101208956B1 (ko) | 엘로티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 | |
NO180194B (no) | 6-[X-(2-hydroksyetyl)aminoalkylÅ-5,11-diokso-5,6-dihydro-11-H-indeno[1,2-cÅisokinoliner og anvendelse derav til fremstilling av medikamenter, samt medikament inneholdende slike kinoliner | |
CN112279860A (zh) | 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 | |
RU2561118C2 (ru) | Производные камптотецина, обладающие противоопухолевой активностью | |
CN108017608B (zh) | 一类黄酮衍生物及其制备方法和用途 | |
CN111704634B (zh) | 一类含有三齿配体和黄嘌呤衍生物配体的金属配合物及其制备方法和医药用途 | |
CN112279861A (zh) | 一种烷基胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用 | |
WO2019007003A1 (zh) | 烷硫端基寡PEG修饰的氨基吡唑并[3,4-d]嘧啶衍生物及抗非小细胞肺癌的应用 | |
CN101331137A (zh) | 抗肿瘤化合物 | |
CN112300187A (zh) | 一种斑蝥素衍生物、其药物组合物及其应用 | |
CN109134470B (zh) | 一种含硒化合物及其用途 | |
CN103304556B (zh) | 含有苯并吡喃的希夫碱类化合物、其制备方法和用途 | |
CN103880793B (zh) | 含呋喃亚胺类化合物及其制备方法和用途 | |
CN103965202B (zh) | 二环稠合杂环化合物、其制备方法及用途 | |
CN109528664B (zh) | 含乌苯美司-抗肿瘤药物协同前药衍生物的冻干粉剂及其制备方法 | |
CN110143948B (zh) | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210129 |
|
RJ01 | Rejection of invention patent application after publication |